Care and feeding of the endocannabinoid system: A systematic review of potential clinical interventions that upregulate the endocannabinoid system

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  McPartland, John M ^a,b   Guy, Geoffrey W ^a   Di Marzo, Vincenzo ^c  

^a Porton Down Science Park   (United Kingdom)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; CAFFEINE; CANNABIS; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; CORTICOSTERONE; DESIPRAMINE; DEXAMETHASONE; DIAZEPAM; DRONABINOL; ENDOCANNABINOID; FLUOXETINE; FLURBIPROFEN; HALOPERIDOL; IBUPROFEN; INDOMETACIN; KETOROLAC; MORPHINE; NALOXONE; NICOTINE; PARACETAMOL; POLYUNSATURATED FATTY ACID; PREGABALIN; PROBIOTIC AGENT; RISPERIDONE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 937; CANNABINOID RECEPTOR;

ACUPUNCTURE; ALCOHOL CONSUMPTION; ANXIETY DISORDER; CHRONIC STRESS; DIET SUPPLEMENTATION; DRUG MECHANISM; EPILEPSY; EXERCISE; HERBAL MEDICINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSOMNIA; LIFESTYLE MODIFICATION; MANIPULATIVE MEDICINE; MASSAGE; MOLECULAR MECHANICS; MUSCLE SPASM; NERVE INJURY; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SMOKING; SUBSTANCE USE; SYSTEMATIC REVIEW; UPREGULATION; WEIGHT CONTROL; \URB 937; ANIMAL; DRUG EFFECTS; METABOLISM;

ANIMALS; ENDOCANNABINOIDS; HUMANS; RECEPTORS, CANNABINOID; UP-REGULATION;

EID: 84898012943     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089566     Document Type: Review

References (344)

1. Glass M, Dragunow M, Faull RL (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77: 299-318. (Pubitemid 27079604)
2. Onaivi ES (2011) Commentary: functional neuronal CB2 cannabinoid receptors in the CNS. Current Neuropharmacology 9: 205-208.
3. Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. British Journal of Pharmacology 160: 467-479.
4. De Petrocellis L, Di Marzo V (2010) Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. Journal of Neuroimmune Pharmacology 5: 103-121.
5. Di Marzo V (1998) 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochimica et Biophysica Acta - Lipids and Lipid Metabolism 1392: 153-175.
6. Di Marzo V, Piscitelli F, Mechoulam R (2011) Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handbook of Experimental Pharmacology: 75-104.
7. Bermudez-Silva FJ, Viveros MP, McPartland JM, de Fonseca FR (2010) The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacology Biochemistry and Behavior 95: 375-382.
8. Russo EB (2004) Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 25: 31-39.
9. Fride E (2004) The endocannabinoid-CB receptor system: Importance for development and in pediatric disease. Neuroendocrinology Letters 25: 24-30.
10. Hill MN, Gorzalka BB (2005) Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 16: 333-352. (Pubitemid 41404805)
11. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, et al. (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108-2114. (Pubitemid 39486563)
12. Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, et al. (2007) Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 32: 1384-1390. (Pubitemid 46788851)
13. Di Filippo M, Pini LA, Pelliccioli GP, Calabresi P, Sarchielli P (2008) Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry 79: 1224-1229.
14. B receptor subunit changes in the globus pallidus in Huntington's disease. Journal of Chemical Neuroanatomy 37: 266-281.
15. Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, et al. (2010) Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. Journal of Nuclear Medicine 51: 1413-1417.
16. Pisani V, Moschella V, Bari M, Fezza F, Galati S, et al. (2010) Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Movement Disorders 25: 920-924.
17. Wong BS, Camilleri M, Eckert D, Carlson P, Ryks M, et al. (2012) Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterology and Motility 24.
18. Gerard N, Pieters G, Goffin K, Bormans G, Van Laere K (2011) Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biological Psychiatry 70: 777-784.
19. Chouker A, Kaufmann I, Kreth S, Hauer D, Feuerecker M, et al. (2010) Motion sickness, stress and the endocannabinoid system. PLoS ONE 5.
20. Sandercock P, Roberts I (2002.) Systematic reviews of animal experiments. Lancet 360: 586. (Pubitemid 35232189)
21. Macleod MR, O'Collins T, Howells DW, Donnan GA (2004) Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35: 1203-1208. (Pubitemid 38543544)
22. McPartland JM, Glass M, Pertwee RG (2007) Meta-analysis of cannabinoid ligand binding affinity and cannabinoid receptor distribution: interspecies differences. British Journal of Pharmacology 152 583-589
23. van der Worp HB, Macleod MR (2011) Preclinical studies of human disease: time to take methodological quality seriously. Journal of Molecular and Cellular Cardiology 51: 449-450.
24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
25. McPartland JM, Pruitt PL (2000) Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study. J Am Osteopath Assoc 100: 89-96. (Pubitemid 30163940)
26. Hornberg JR (2013) Measuring behaviour in rodents: towards translational neuropsychiatric research. Behavioural Brain Research 236: 295-306.
27. Fowler CJ, Janson U, Johnson RM, Wahlstrom G, Stenstrom A, et al. (1999) Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen. Archives of Biochemistry and Biophysics 362: 191-196. (Pubitemid 29394346)
28. Bertolacci L, Romeo E, Veronesi M, Magotti P, Albani C, et al. (2013) A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase. Journal of the American Chemical Society 135: 22-25.
29. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, et al. (2002) Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277: 44877-44885. (Pubitemid 36159083)
30. Sang N, Zhang J, Chen C (2006) PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. Journal of Physiology-London 572: 735-745.
31. Hu SSJ, Bradshaw HB, Chen JSC, Tan B, Walker JM (2008) Prostaglandin E-2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NF kappa B activity. British Journal of Pharmacology 153: 1538-1549. (Pubitemid 351481525)
32. Gatta L, Piscitelli F, Giordano C, Boccella S, Lichtman A, et al. (2012) Discovery of prostamide F-2 alpha and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. Plos One 7.
33. Kim J, Alger BE (2004) Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nature Neuroscience 7: 697-698. (Pubitemid 38859050)
34. Gühring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, et al. (2002) A role for endocannabinoids in indomethacin-induced spinal antinociception. European Journal of Pharmacology 454: 153-163. (Pubitemid 35287474)
35. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, et al. (2003) Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. European Journal of Neuroscience 17: 597-604. (Pubitemid 36255896)
36. Ahn DK, Choi HS, Yeo SP, Woo YW, Lee MK, et al. (2007) Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception. Pain 132: 23-32. (Pubitemid 47494555)
37. Guindon J, Hohmann AG (2009) The endocannabinoid system and pain. CNS & Neurological Disorders-Drug Targets 8: 403-421.
38. Sasso O, Bertorelli R, Bandiera T, Scarpelli R, Colombano G, et al. (2012) Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacological Research 65: 553-563.
39. Green K, Kearse EC, McIntyre OL (2001) Interaction between Delta-9-tetrahydrocannabinol and indomethacin. Ophthalmic Research 33: 217-220. (Pubitemid 32678989)
40. Perez Reyes M, Burstein SH, White WR, Mcdonald SA, Hicks RE (1991) Antagonism of marihuana effects by indomethacin in humans. Life Sciences 48: 507-515.
41. Easley RB, Altemeier WA 3rd (2000) Central nervous system manifestations of an ibuprofen overdose reversed by naloxone. Pediatr Emerg Care 16: 39-41. (Pubitemid 30102109)
42. McPartland JM, Blanchon DJ, Musty RE (2008) Cannabimimetic effects modulated by cholinergic compounds. Addiction Biology 13: 411-415.
43. Högestätt ED, Jonsson BAG, Ermund A, Andersson DA, Bjork H, et al. (2005) Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. Journal of Biological Chemistry 280: 31405-31412. (Pubitemid 41291881)
44. Dania M, Guindon J, Lambert C, Beaulieu P (2007) The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. European Journal of Pharmacology 573: 214-215. (Pubitemid 47464223)
45. Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A (2006) The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. European Journal of Pharmacology 531: 280-281. (Pubitemid 43202247)
46. Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, et al. (2008) Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 139: 190-200.
47. Umathe SN, Manna SSS, Utturwar KS, Jain NS (2009) Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors. Progress in Neuro-Psychopharmacology & Biological Psychiatry 33: 1191-1199.
48. 9-tetrahydrocannabiorcol. Nature Communications 2: 551.
49. Gould GG, Seillier A, Weiss G, Giuffrida A, Burke TF, et al. (2012) Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry 38: 260-269.
50. Wang S, Lim G, Mao J, Sung B, Yang L (2007) Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats. Pain 131: 96-105. (Pubitemid 47193211)
51. Wu RW, Lin TP, Ko JY, Yeh DW, Chen MW, et al. (2011) Cannabinoid receptor 1 regulates ERK and GSK-3 beta-dependent glucocorticoid inhibition of osteoblast differentiation in murine MC3T3-E1 cells. Bone 49: 1255-1263.
52. Ko JY, Wu RW, Kuo SJ, Chen MW, Yeh DW, et al. (2012) Cannabinoid receptor 1 mediates glucocorticoid-induced bone loss in rats by perturbing bone mineral acquisition and marrow adipogenesis. Arthritis and Rheumatism 64: 1204-1214.
53. Di S, Malcher-Lopes R, Halmos KC, Tasker JG (2003) Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. Journal of Neuroscience 23: 4850-4857. (Pubitemid 36793211)
54. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG (2005) Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 146: 4292-4301. (Pubitemid 41324025)
55. Malcher-Lopes R, Di S, Marcheselli VS, Weng FJ, Stuart CT, et al. (2006) Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. Journal of Neuroscience 26: 6643-6650. (Pubitemid 44318346)
56. Wang J, Shen RY, Haj-Dahmane S (2012) Endocannabinoids mediate the glucocorticoid-induced inhibition of excitatory synaptic transmission to dorsal raphe serotonin neurons. Journal of Physiology-London 590: 5795-5808.
57. Hill MN, Karatsoreos IN, Hillard CJ, McEwen BS (2010) Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo. Psychoneuroendocrinology 35: 1333-1338.
58. Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, et al. (2011) Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. Journal of Neuroscience 31: 10506-10515.
59. 1 receptor density in the hippocampus. Hippocampus 18: 221-226.
60. Atsak P, Hauer D, Campolongo P, Schelling G, McGaugh JL, et al. (2012) Glucocorticoids interact with the hippocampal endocannabinoid system in impairing retrieval of contextual fear memory. Proceedings of the National Academy of Sciences of the United States of America 109: 3504-3509.
61. Bowles NP, Hill MN, Bhagat SM, Karatsoreos IN, Hillard CJ, et al. (2012) Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice. Neuroscience 204: 83-89.
62. Hong S, Fan J, Kemmerer ES, Evans S, Li Y, et al. (2009) Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat. Gut 58: 202-210.
63. 9-THC induced Fos expression in rat brain. Neuropharmacology 44: 264-274.
64. 9-tetrahydrocannabinol and morphine. Journal of Pharmacology and Experimental Therapeutics 297: 121-127.
65. Fattore L, Vigano D, Fadda P, Rubino T, Fratta W, et al. (2007) Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. European Journal of Neuroscience 25: 2191-2200. (Pubitemid 46581742)
66. Schoffelmeer ANM, Hogenboom F, Wardeh G, De Vries TJ (2006) Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51: 773-781. (Pubitemid 44308340)
67. Viganò D, Valenti M, Cascio MG, Di Marzo V, Parolaro D, et al. (2004) Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. European Journal of Neuroscience 20: 1849-1857. (Pubitemid 39471578)
68. Gonzalez S, Fernández-Ruiz J, Sparpaglione V, Parolaro D, Ramos JA (2002) Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB1 receptor binding and mRNA levels. Drug and Alcohol Dependence 66: 77-84. (Pubitemid 34159259)
69. Chu J, Zheng H, Zhang YH, Loh HH, Law PY (2010) Agonist-dependent muopioid receptor signaling can lead to heterologous desensitization. Cellular Signalling 22: 684-696.
70. Berrendero F, Mendizabal V, Murtra P, Kieffer BL, Maldonado R (2003) Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice. Eur J Neurosci 18: 2197-2202. (Pubitemid 38117393)
71. Marini P, Moriello AS, Cristino L, Palmery M, De Petrocellis L, et al. (2009) Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: interactions with muscarinic and delta-opioid receptors. Biochimica Et Biophysica Acta-Molecular Cell Research 1793: 1289-1303.
72. Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, et al. (2004) CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. British Journal of Pharmacology 143: 343-350. (Pubitemid 39424822)
73. Justinova Z, Munzar P, Panlilio LV, Yasar S, Redhi GH, et al. (2008) Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB1-receptor antagonist rimonabant. Neuropsychopharmacology 33: 2870-2877.
74. 9- Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. European Journal of Pharmacology 506: 63-69.
75. Solinas M, Zangen A, Thiriet N, Goldberg SR (2004) beta-Endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol. European Journal of Neuroscience 19: 3183-3192. (Pubitemid 38859535)
76. Welch SP, Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. Journal of Pharmacology and Experimental Therapeutics 262: 10-18.
77. Pugh G, Smith PB, Dombrowski DS, Welch SP (1996) The role of endogenous opioids in enhancing the antinociception produced by the combination of delta-9-tetrahydrocannabinol and morphine in the spinal cord. Journal of Pharmacology and Experimental Therapeutics 279: 608-616. (Pubitemid 27166831)
78. 9-tetrahydrocannabinol: dose-response analysis and receptor identification. Journal of Pharmacology and Experimental Therapeutics 289: 859-867.
79. 9- tetrahydrocannabinol and morphine in the arthritic rat. European Journal of Pharmacology 567: 125-130.
80. 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ- and κ-opioid receptors. European Journal of Pharmacology 318: 11-16.
81. Loewe WS (1928) Die quantitative Problem der Pharmakologie. Ergebnisse der Physiologie 27: 47-187.
82. Loewe WS (1940) Synergism of cannabis and butyl-bromathyl-barbituric acid. Journal of the American Pharmaceutical Association (Scientific edition) 29: 162-163.
83. Loewe WS (1944) Studies on the pharmacology of marihuana. In: Committee L, editor. The Marihuana Problem in the City of New York. Lancaster, PA: Jaques Cattell Press. pp. 149-212.
84. Loewe WS, Modell W (1941) The action of chemical components of cannabis extracts. Journal of Pharmacology and Experimental Therapeutics 72: 72.
85. Loewe WS (1945) Marihuana activity of cannabinol. Science 102: 615-616.
86. Roberts JD, Gennings C, Shih M (2006) Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. European Journal of Pharmacology 530: 54-58. (Pubitemid 43037124)
87. Berrendero F, Maldonado R (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology 163: 111-117. (Pubitemid 34985320)
88. 9-tetrahydrocannabinol-induced antinociception in mice. Neuropharmacology 37: 215-222.
89. Haney M, Bisaga A, Foltin RW (2003) Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 166: 77-85. (Pubitemid 36286723)
90. Cooper ZD, Haney M (2010) Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology (Berl) 211: 141-148.
91. 9- tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. British Journal of Pharmacology 124: 1419-1424.
92. Goddard M, Smith PF, Ashton JC (2010) Behavioural effects of coadministration of delta 9-tetrahydrocannabinol with fluoxetine in rats. Pharmacology 86: 125-128.
93. Hill MN, Ho WSV, Hillard CJ, Gorzalka BB (2008) Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. Journal of Neural Transmission 115: 1673-1679.
94. Rodriguez-Gaztelumendi A, Rojo ML, Pazos A, Diaz A (2009) Altered CB1 receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. Journal of Neurochemistry 108: 1423-1433.
95. Hesketh SA, Brennan AK, Jessop DS, Finn DP (2008) Effects of chronic treatment with citalopram on cannabinoid and opioid receptor-mediated G-protein coupling in discrete rat brain regions. Psychopharmacology 198: 29-36.
96. Wang W, Sun DL, Pan B, Roberts CJ, Sun XL, et al. (2010) Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress. Neuropsychopharmacology 35: 2249-2261.
97. 1A receptor-dependent mechanisms. Molecular Pharmacology 77: 424-434.
98. Hill MN, Ho WSV, Sinopoli KJ, Viau V, Hillard CJ, et al. (2006) Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31: 2591-2599. (Pubitemid 44764156)
99. Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, et al. (2008) Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. Journal of Neurochemistry 106: 2322-2336.
100. Gobshtis N, Ben-Shabat S, Fride E (2007) Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness. European Journal of Pharmacology 554: 155-163. (Pubitemid 44879411)
101. Hill MN, Barr AM, Ho WSV, Carrier EJ, Gorzalka BB, et al. (2007) Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. Journal of Neurochemistry 103: 47-56. (Pubitemid 47404194)
102. Gray GA, Hedley D, Pertwee RG (1987) Enhancement of the hypothermic response of mice to delta-9-tetrahydrocannabinol by subhypothermic doses of chlorpromazine and phentolamine. Neuropharmacology 23: 229-235. (Pubitemid 17040645)
103. Andersson M, Terasmaa A, Fuxe K, Stromberg I (2005) Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia. J Neurosci Res 82: 264-272. (Pubitemid 41648765)
104. Sundram S, Copolov D, Dean B (2005) Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 371: 428-433. (Pubitemid 41187515)
105. Schulze DR, Carroll FI, McMahon LR (2012) Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys. Psychopharmacology 222: 425-438.
106. Secher A, Husum H, Holst B, Egerod KL, Mellerup E (2010) Risperidone treatment increases CB1 receptor binding in rat brain. Neuroendocrinology 91: 155-168.
107. Cheng MC, Liao DL, Hsiung CA, Chen CY, Liao YC, et al. (2008) Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. International Journal of Neuropsychopharmacology 11: 207-216. (Pubitemid 351231829)
108. Rodrigues LCD, Conti CL, Nakamura-Palacios EM (2011) Clozapine and SCH 23390 prevent the spatial working memory disruption induced by Delta(9)-THC administration into the medial prefrontal cortex. Brain Research 1382: 230-237.
109. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, et al. (2008) Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of delta-9-tetrahydrocannabinol in humans. Psychopharmacology 198: 587-603.
110. Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, et al. (2010) Central nervous system effects of haloperidol on THC in healthy male volunteers. Journal of Psychopharmacology 24: 1697-1708.
111. 9- tetrahydrocannabinol? Journal of Psychopharmacology 26: 1307-1316.
112. Naderi N, Haghparast A, Saber-Tehrani A, Rezaii N, Alizadeh AM, et al. (2008) Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 89: 64-75.
113. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, et al. (2009) Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: possible involvement of the endocannabinoid and endovanilloid systems. Neurobiology of Disease 36: 70-80.
114. Garcia-Gutierrez MS, Manzanares J (2010) The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines. Journal of Psychopharmacology 24: 757-765.
115. Urigüen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46: 966-973. (Pubitemid 38471950)
116. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, et al. (2009) Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34: 593-606.
117. Pertwee RG, Greentree SG, Swift PA (1988) Drugs that stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol-induced to produce marked catalepsy in mice. Neuropharmacology 27: 1265-1270. (Pubitemid 19018313)
118. Sulkowski A, Vachon L, Rich ES (1977) Propranolol effects on acute marihuana intoxication in man. Psychopharmacology (Berl) 23: 47-53. (Pubitemid 8072151)
119. Weis F, Beiras-Fernandez A, Hauer D, Hornuss C, Sodian R, et al. (2010) Effect of anaesthesia and cardiopulmonary bypass on blood endocannabinoid concentrations during cardiac surgery. British Journal of Anaesthesia 105: 139-144.
120. Pryor GT, Husain S, Larsen FF, McKenzie CE, Carr JD, et al. (1977) Interactions between delta9-tetrahydrocannabinol and phencyclidine hydrochloride in rats. Pharmacology Biochemistry and Behavior 6: 123-136. (Pubitemid 8079137)
121. McPartland JM, Pruitt PL (1997) Medical marijuana and its use by the immunocompromised. Altern Ther Health Med 3: 39-45. (Pubitemid 127529329)
122. Novelli GP, Peduto VA, Bertol E, Mari F, Pieraccioli E (1983) Analgesic interaction between nitrous oxide and delta-9-tetrahydrocannabinol in the rat. British Journal of Anaesthesia 55: 997-1000. (Pubitemid 13017012)
123. Naderi N, Ahari FA, Shafaghi B, Najarkolaei AH, Motamedi F (2008) Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. Journal of Neural Transmission 115: 1501-1511.
124. Goffin K, Bormans G, Casteels C, Bosier B, Lambert DM, et al. (2008) An in vivo [18F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam. Neuropharmacology 54: 1103-1106.
125. Pertwee RG, Browne SE, Ross TM, Stretton CD (1991) An investigation of the involvement of GABA in certain pharmacological effects of delta-9-tetrahydrocannabinol. Pharmacology Biochemistry and Behavior 40: 581-585.
126. 9-THC. Drug and Alcohol Dependence 122: 61-69.
127. Luszczki JJ, Florek-Luszczki M (2012) Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212-2 mesylate in the hot-plate test in mice: an isobolographic analysis. Pharmacological Reports 64: 723-732.
128. Banni S, Carta G, Murru E, Cordeddu L, Giordano E, et al. (2012) Vagus nerve stimulation reduces body weight and fat mass in rats. Plos One 7.
129. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ (2010) Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. American Journal of Physiology- Gastrointestinal and Liver Physiology 299: G63-G69.
130. Riediger ND, Othman RA, Suh M, Moghadasian MH (2009) A systemic review of the roles of n-3 fatty acids in health and disease. Journal of the American Dietetic Association 109: 668-679.
131. Alvheim AR, Malde MK, Osei-Hyiaman D, Lin YH, Pawlosky RJ, et al. (2012) Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity. Obesity 20: 1984-1994.
132. Hutchins-Wiese HL, Li Y, Hannon K, Watkins BA (2012) Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. Journal of Nutritional Biochemistry 23: 986-993.
133. Wood JT, Williams JS, Pandarinathan L, Janero DR, Lammi-Keefe CJ, et al. (2010) Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. Journal of Lipid Research 51: 1416-1423.
134. Piscitelli F, Carta G, Bisogno T, Murru E, Cordeddu L, et al. (2011) Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutrition & Metabolism 8.
135. Lafourcade M, Larrieu T, Mato S, Duffaud A, Sepers M, et al. (2011) Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nature Neuroscience 14: 345-350.
136. Larrieu T, Madore C, Joffre C, Laye S (2012) Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signaling pathway in the brain and associated anxiety-like behavior in mice. Journal of Physiology and Biochemistry 68: 671-681.
137. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, et al. (2001) Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets (vol 98, pg 6402, 2001). Proceedings of the National Academy of Sciences of the United States of America 98: 7647-7647.
138. Bisogno T, Delton Vandenbroucke I, Milone A, La Garde M, Di Marzo V (1999) Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Archives of Biochemistry and Biophysics 370: 300-307. (Pubitemid 29491438)
139. Brown I, Cascio MG, Wahle KWJ, Smoum R, Mechoulam R, et al. (2010) Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 31: 1584-1591.
140. Kim HY, Spector AA (2013) Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. Prostaglandins Leukotrienes and Essential Fatty Acids 88: 121-125.
141. Schuchardt JP, Schneider I, Meyer H, Neubronner J, von Schacky C, et al. (2011) Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations-a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis 10: 145.
142. Batetta B, Griinari M, Carta G, Murru E, Ligresti A, et al. (2009) Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. Journal of Nutrition 139: 1495-1501.
143. Di Marzo V, Griinari M, Carta G, Murru E, Ligresti A, et al. (2010) Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. International Dairy Journal 20: 231-235.
144. Banni S, Carta G, Murru E, Cordeddu L, Giordano E, et al. (2011) Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutr Metab (Lond) 8: 7.
145. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, et al. (2007) Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13: 35-37. (Pubitemid 46067383)
146. Palermo FA, Mosconi G, Avella MA, Carnevali O, Verdenelli MC, et al. (2011) Modulation of cortisol levels, endocannabinoid receptor 1A, proopiomelanocortin and thyroid hormone receptor alpha mRNA expressions by probiotics during sole (Solea solea) larval development. General and Comparative Endocrinology 171: 293-300.
147. Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, et al. (2010) The endocannabinoid system links gut microbiota to adipogenesis. Molecular Systems Biology 6.
148. Crouzin N, de Jesus Ferreira MC, Cohen-Solal C, M'Kadmi C, Bernad N, et al. (2011) alpha-tocopherol and alpha-tocopheryl phosphate interact with the cannabinoid system in the rodent hippocampus. Free Radic Biol Med 51: 1643-1655.
149. Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier G, et al. (1998) Trick or treat from food endocannabinoids? Nature 396: 636-637.
150. Crozier Willi G, Berger A, Di Marzo V, Bisogno T, De Petrocellis L, et al. (2001) Lipids in neural function: modulation of behavior by oral administration of endocannabinoids found in foods. Nestle Nutr Workshop Ser Clin Perform Programme: 169-184; discussion 185-167.
151. Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, et al. (2001) Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 419: 207-214. (Pubitemid 32568220)
152. Carr RL, Borazjani A, Ross MK (2011) Effect of developmental chlorpyrifos exposure, on endocannabinoid metabolizing enzymes, in the brain of juvenile rats. Toxicological Sciences 122: 112-120.
153. Quistad CB, Sparks SE, Casida JE (2001) Fatty acid amide hydrolase inhibition by neurotoxic organophosphorus pesticides. Toxicology and Applied Pharmacology 173: 48-55. (Pubitemid 32480364)
154. Dhopeshwarkar AS, Jain S, Liao CY, Ghose SK, Bisset KM, et al. (2011) The actions of benzophenanthridine alkaloids, piperonyl butoxide and (S)-methoprene at the G-protein coupled cannabinoid CB1 receptor in vitro. European Journal of Pharmacology 654: 26-32.
155. 1) receptor of mammalian brain: inhibition by phthalate esters in vitro. Neurochemistry International 59: 706-713.
156. Simao da Silva KAB, Paszcuk AF, Passos GF, Silva ES, Bento AF, et al. (2011) Activation of cannabinoid receptors by the pentacyclic triterpene alpha,beta-amyrin inhibits inflammatory and neuropathic persistent pain in mice. Pain 152: 1872-1887.
157. Meschler JP, Howlett AC (1999) Thujone exhibits low affinity for cannabinoid receptors but fails to evoke cannabimimetic responses. Pharmacology Biochemistry and Behavior 62: 473-480. (Pubitemid 29117189)
158. King AR, Dotsey EY, Lodola A, Jung KM, Ghomian A, et al. (2009) Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol 16: 1045-1052.
159. Capasso R, Borrelli F, Cascio MG, Aviello G, Huben K, et al. (2008) Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB1 receptors. British Journal of Pharmacology 155: 681-689.
160. Fichna J, Dicay M, Lewellyn K, Janecka A, Zjawiony JK, et al. (2012) Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflammatory Bowel Diseases 18: 1137-1145.
161. Thors L, Burston JJ, Alter BJ, McKinney MK, Cravatt BF, et al. (2010) Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. British Journal of Pharmacology 160: 549-560.
162. Korte G, Dreiseitel A, Schreier P, Oehme A, Locher S, et al. (2009) An examination of anthocyanins' and anthocyanidins' affinity for cannabinoid receptors. Journal of Medicinal Food 12: 1407-1410.
163. Korte G, Dreiseitel A, Schreier P, Oehme A, Locher S, et al. (2010) Tea catechins' affinity for human cannabinoid receptors. Phytomedicine 17: 19-22.
164. Ligresti A, Villano R, Allara M, Ujvary I, Di Marzo V (2012) Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB1 receptor ligand. Pharmacological Research 66: 163-169.
165. Hassanzadeh P, Hassanzadeh A (2012) The CB1 receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin. Neurochemical Research 37: 1112-1120.
166. Prather PL, Seely KA, Levi MS (2009) The dietary polyphenols transresveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists (vol 330, pg 31, 2009). Journal of Pharmacology and Experimental Therapeutics 331: 1147-1147.
167. Botta B, Gacs-Baitz E, Vinciguerra V, Delle Monache G (2003) Three isoflavanones with cannabinoid-like moieties from Desmodium canum. Phytochemistry 64: 599-602. (Pubitemid 37168983)
168. Muhammad I, Li XC, Dunbar DC, ElSohly MA, Khan IA (2001) Antimalarial (+)-trans-hexahydrodibenzopyran derivatives from Machaerium multiflorum. Journal of Natural Products 64: 1322-1325. (Pubitemid 33029215)
169. Bohlmann F, Hoffmann E (1979) Cannabigerol-ähnliche verbendungen aus Helichrysum umbraculigerum. Phytochemistry 18: 1371-1374.
170. Iwata N, Kitanaka S (2011) New cannabinoid-like chromane and chromene derivatives from Rhododendron anthopogonoides. Chemical & Pharmaceutical Bulletin 59: 1409-1412.
171. Harinantenaina L, Takahara Y, Nishizawa T, Kohchi C, Soma GI, et al. (2006) Chemical constituents of malagasy liverworts, Part V: Prenyl bibenzyls and clerodane diterpenoids with nitric oxide inhibitory activity from Radula appressa and Thysananthus spathulistipus. Chemical & Pharmaceutical Bulletin 54: 1046-1049.
172. Toyota M, Shimamura T, Ishii H, Renner M, Braggins J, et al. (2002) New bibenzyl cannabinoid from the New Zealand liverwort Radula marginata. Chemical & Pharmaceutical Bulletin 50: 1390-1392. (Pubitemid 41702045)
173. Gao JT, Leon F, Radwan MM, Dale OR, Husni AS, et al. (2011) Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens. Journal of Natural Products 74: 1636-1639.
174. Lin H, Ji-Kai L (2001) Two novel phenylacetoxylated p-terphenyls from Thelephora ganbajun Zang. Z Naturforsch C 56: 983-987. (Pubitemid 34115479)
175. Quaghebeur K, Coosemans J, Toppet S, Compernolle F (1994) Cannabiorci- and 8-chlorocannabiorcichromenic acid as fungal antagonists from Cylindrocarpon olidum. Phytochemistry 37: 159-161. (Pubitemid 2148846)
176. Leonti M, Casu L, Raduner S, Cottiglia F, Floris C, et al. (2010) Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. Biochemical Pharmacology 79: 1815-1826.
177. Zank TK, Zahringer U, Lerchl J, Heinz E (2000) Cloning and functional expression of the first plant fatty acid elongase specific for Delta(6)-polyunsaturated fatty acids. Biochemical Society Transactions 28: 654-658. (Pubitemid 32163220)
178. di Tomaso E, Beltramo M, Piomelli D (1996) Brain cannabinoids in chocolate. Nature 382: 677-678. (Pubitemid 26282162)
179. Nakane S, Tanaka T, Satouchi K, Kobayashi Y, Waku K, et al. (2000) Occurrence of a novel cannabimimetic molecule 2- sciadonoylglycerol (2-eicosa-5′, 11′, 14′-trienoylglycerol) in the umbrella pine Sciadopitys verticillata seeds. Biological & Pharmaceutical Bulletin 23: 758-761. (Pubitemid 30435085)
180. Gutierrez M, Pereira AR, Debonsi HM, Ligresti A, Di Marzo V, et al. (2011) Cannabinomimetic lipid from a marine cyanobacterium. Journal of Natural Products 74: 2313-2317.
181. Sitachitta N, Gerwick WH (1998) Grenadadiene and grenadamide, cyclopropyl-containing fatty acid metabolites from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 61: 681-684. (Pubitemid 28262047)
182. Soderstrom K, Murray TF, Yoo HD, Ketchum S, Milligan K, et al. (1997) Discovery of novel cannabinoid receptor ligands from diverse marine organisms. Advances in Experimental Medicine and Biology 433: 73-77. (Pubitemid 28231786)
183. Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, et al. (2006) Alkylamides from Echinacea are a new class of cannabinomimetics - cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. Journal of Biological Chemistry 281: 14192-14206. (Pubitemid 43848347)
184. Chicca A, Raduner S, Pellati F, Strompen T, Altmann KH, et al. (2009) Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. International Immunopharmacology 9: 850-858.
185. Hohmann J, Redei D, Forgo P, Szabo P, Freund TF, et al. (2011) Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors. Phytochemistry 72: 1848-1853.
186. Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, et al. (2008) Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences of the United States of America 105: 9099-9104.
187. Bento AF, Marcon R, Dutra RC, Claudino RF, Cola M, et al. (2011) Beta-caryophyllene inhibits dextran sulfate sodium-Induced colitis in mice through CB2 receptor activation and PPAR gamma pathway. American Journal of Pathology 178: 1153-1166.
188. Horvath B, Mukhopadhyay P, Kechrid M, Patel V, Tanchian G, et al. (2012) β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner. Free Radical Biology and Medicine 52: 1325-1333.
189. Katsuyama S, Mizoguchi H, Kuwahata H, Komatsu T, Nagaoka K, et al. (2013) Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception. European Journal of Pain 17: 664-675.
190. Rollinger JM, Schuster D, Danzl B, Schwaiger S, Markt P, et al. (2009) In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Med 75: 195-204.
191. Palu AK, Kim AH, West BJ, Deng SX, Jensen J, et al. (2008) The effects of Morinda citrifolia L. (noni) on the immune system: its molecular mechanisms of action. Journal of Ethnopharmacology 115: 502-506. (Pubitemid 350299089)
192. Quartu M, Serra MP, Boi M, Pillolla G, Melis T, et al. (2012) Effect of acute administration of Pistacia lentiscus L. essential oil on rat cerebral cortex following transient bilateral common carotid artery occlusion. Lipids in Health and Disease 11.
193. Sepe N, De Petrocellis L, Montanaro F, Cimino G, Di Marzo V (1998) Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs - Possible implications for mollusc physiology and seafood industry. Biochimica et Biophysica Acta Lipids and Lipid Metabolism 1389: 101-111. (Pubitemid 28022470)
194. Bisogno T, Ventriglia M, Milone A, Mosca M, Cimino G, et al. (1997) Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochimica et Biophysica Acta Lipids and Lipid Metabolism 1345: 338-348. (Pubitemid 27171210)
195. Matias I, McPartland JM, Di Marzo V (2005) Occurrence and possible biological role of the endocannabinoid system in the sea squirt Ciona intestinalis. Journal of Neurochemistry 93: 1141-1156. (Pubitemid 40776569)
196. Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TTY, et al. (2010) Endogenous cannabinoid signaling is essential for stress adaptation. Proceedings of the National Academy of Sciences of the United States of America 107: 9406-9411.
197. Patel S, Roelke CT, Rademacher DJ, Hillard CJ (2005) Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. European Journal of Neuroscience 21: 1057-1069. (Pubitemid 40461057)
198. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, et al. (2005) Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30: 508-515. (Pubitemid 40271153)
199. Patel S, Kingsley PJ, Mackie K, Marnett LJ, Winder DG (2009) Repeated homotypic stress elevates 2-arachidonoylglycerol levels and enhances short-term endocannabinoid signaling at iInhibitory synapses in basolateral amygdala. Neuropsychopharmacology 34: 2699-2709.
200. Evanson NK, Tasker JG, Hill MN, Hillard CJ, Herman JP (2010) Fast feedback inhibition of the HPA axis by glucocorticoids Is mediated by endocannabinoid signaling. Endocrinology 151: 4811-4819.
201. Reich CG, Taylor ME, McCarthy MM (2009) Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats. Behavioural Brain Research 203: 264-269.
202. Sciolino NR, Bortolato M, Eisenstein SA, Fu J, Oveisi F, et al. (2010) Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats. Neuroscience 168: 371-386.
203. Zoppi S, Nievas BGP, Madrigal JLM, Manzanares J, Leza JC, et al. (2011) Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. Neuropsychopharmacology 36: 805-818.
204. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, et al. (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biological Psychiatry 62: 1103-1110. (Pubitemid 350029716)
205. Lee TTY, Hill MN (2013) Age of stress exposure modulates the immediate and sustained effects of repeated stress on corticolimbic cannabinoid CB1 receptor binding in male rats. Neuroscience 249: 106-114.
206. Hong SS, Zheng G, Wu XY, Snider NT, Owyang C, et al. (2011) Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. Gastroenterology 140: 627-U371.
207. Dubreucq S, Matias I, Cardinal P, Haring M, Lutz B, et al. (2012) Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 37: 1885-1900.
208. Rossi S, De Chiara V, Musella A, Kusayanagi H, Mataluni G, et al. (2008) Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. Journal of Neuroscience 28: 7284-7292.
209. Hu W, Zhang MY, Czeh B, Zhang WQ, Flugge G (2011) Chronic restraint stress impairs endocannabinoid mediated suppression of GABAergic signaling in the hippocampus of adult male rats. Brain Research Bulletin 85: 374-379.
210. Wamsteeker JI, Kuzmiski JB, Bains JS (2010) Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus. Journal of Neuroscience 30: 11188-11196.
211. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, et al. (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112. (Pubitemid 40910518)
212. Connell K, Bolton N, Olsen D, Piomelli D, Hohmann AG (2006) Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. Neuroscience Letters 397: 180-184.
213. Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G, et al. (2009) Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proceedings of the National Academy of Sciences of the United States of America 106: 4888-4893.
214. Coddington E, Lewis C, Rose JD, Moore FL (2007) Endocannabinoids mediate the effects of acute stress and corticosterone on sex behavior. Endocrinology 148: 493-500. (Pubitemid 46143154)
215. Wang MN, Hill MN, Zhang LH, Gorzalka BB, Hillard CJ, et al. (2012) Acute restraint stress enhances hippocampal endocannabinoid function via glucocorticoid receptor activation. Journal of Psychopharmacology 26: 56-70.
216. Bradshaw HB, Rimmerman N, Krey JF, Walker JM (2006) Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 291: R349-R358. (Pubitemid 44035641)
217. Dunnett AJ, Roy D, Stewart A, McPartland JM (2007) The diagnosis of fibromyalgia in women may be influenced by menstrual cycle phase. Journal of Bodywork and Movement Therapies 11: 99-105.
218. McPartland JM, Giuffrida A, King J, Skinner E, Scotter J, et al. (2005) Cannabimimetic effects of osteopathic manipulative treatment. Journal of the American Osteopathic Association 105: 283-291. (Pubitemid 41105502)
219. Trezza V, Damsteegt R, Manduca A, Petrosino S, Van Kerkhof LWM, et al. (2012) Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. Journal of Neuroscience 32: 14899-14908.
220. Navarro M, Hernández E, Muñoz RM, del Arco I, Villanúa MA, et al. (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport 8: 491-496. (Pubitemid 27180108)
221. Park HJ, Park HJ, Chae Y, Kim JW, Lee H, et al. (2011) Effect of acupuncture on hypothalamic-pituitary-adrenal system in maternal separation rats. Cell Mol Neurobiol 31: 1123-1127.
222. Chen L, Zhang J, Li F, Qiu Y, Wang L, et al. (2009) Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats. Journal of Pain 10: 732-739.
223. Zhang J, Chen L, Su TF, Cao FY, Meng XF, et al. (2010) Electroacupuncture increases CB2 receptor expression on keratinocytes and infiltrating inflammatory cells in inflamed skin tissues of rats. Journal of Pain 11: 1250-1258.
224. Su TF, Zhang LH, Peng M, Wu CH, Pan W, et al. (2011) Cannabinoid CB2 receptors contribute to upregulation of beta-endorphin in inflamed skin tissues by electroacupuncture. Molecular Pain 7.
225. Fu LW, Longhurst JC (2009) Electroacupuncture modulates vlPAG release of GABA through presynaptic cannabinoid CB1 receptors. J Appl Physiol 106: 1800-1809.
226. Wang QA, Li XY, Chen YK, Wang F, Yang QZ, et al. (2011) Activation of epsilon protein kinase C-mediated anti-apoptosis is involved in rapid tolerance induced by electroacupuncture pretreatment through cannabinoid receptor type 1. Stroke 42: 389-396.
227. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, et al. (2005) Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Neuropharmacology 48: 1154-1163. (Pubitemid 40725988)
228. Di Marzo V (2011) Endocannabinoids: an appetite for fat. Proc Natl Acad Sci U S A 108: 12567-12568.
229. Di Marzo V, Matias I (2005) Endocannabinoid control of food intake and energy balance. Nature Neuroscience 8: 585-589. (Pubitemid 40594198)
230. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, et al. (2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. International Journal of Obesity 31: 692-699. (Pubitemid 46482358)
231. Massa F, Mancini G, Schmidt H, Steindel F, Mackie K, et al. (2010) Alterations in the hippocampal endocannabinoid system in diet-Induced obese mice. Journal of Neuroscience 30: 6273-6281.
232. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843. (Pubitemid 41401077)
233. Bennetzen MF, Wellner N, Ahmed SS, Ahmed SM, Diep TA, et al. (2011) Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss. International Journal of Obesity 35: 1377-1384.
234. Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, et al. (2009) Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52: 213-217.
235. You TJ, Disanzo BL, Wang XW, Yang RZ, Gong DW (2011) Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise. Lipids in Health and Disease 10.
236. Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, et al. (2012) Endocannabinoids measurement in human saliva as potential biomarker of obesity. Plos One 7.
237. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A (2003) Exercise activates the endocannabinoid system. Neuroreport 14: 2209-2211.
238. Heyman E, Gamelin FX, Goekint M, Piscitelli F, Roelands B, et al. (2012) Intense exercise increases circulating endocannabinoid and BDNF levels in humans - possible implications for reward and depression. Psychoneuroendocrinology 37: 844-851.
239. Feuerecker M, Hauer D, Toth R, Demetz F, Holzl J, et al. (2012) Effects of exercise stress on the endocannabinoid system in humans under field conditions. European Journal of Applied Physiology 112: 2777-2781.
240. Raichlen DA, Foster AD, Gerdeman GL, Seillier A, Giuffrida A (2012) Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high'. Journal of Experimental Biology 215: 1331-1336.
241. Raichlen DA, Foster AD, Seillier A, Giuffrida A, Gerdeman GL (2013) Exercise-induced endocannabinoid signaling is modulated by intensity. European Journal of Applied Physiology 113: 869-875.
242. Ferrer B, Bermudez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, et al. (2007) Regulation of brain anandamide by acute administration of ethanol. Biochemical Journal 404: 97-104. (Pubitemid 46788089)
243. Basavarajappa BS, Ninan I, Arancio O (2008) Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons. Journal of Neurochemistry 107: 1001-1013.
244. Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL, et al. (2005) Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo. Psychopharmacology 183: 368-377. (Pubitemid 41660423)
245. Perra S, Pillolla G, Luchicchi A, Pistis M (2008) Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system. Alcoholism-Clinical and Experimental Research 32: 443-449. (Pubitemid 351300988)
246. Yin HH, Park BS, Adermark L, Lovinger DM (2007) Ethanol reverses the direction of long-term synaptic plasticity in the dorsomedial striatum. Eur J Neurosci 25: 3226-3232. (Pubitemid 46872785)
247. Clarke RBC, Adermark L (2010) Acute ethanol treatment prevents endocannabinoid-mediated long-lasting disinhibition of striatal output. Neuropharmacology 58: 799-805.
248. Basavarajappa BS, Cooper TB, Hungund BL (1998) Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane. Brain Res 793: 212-218. (Pubitemid 28294088)
249. Basavarajappa BS, Hungund BL (1999) Down-regulation of cannabinoid receptor agonist-stimulated [35S]GTP gamma S binding in synaptic plasma membrane from chronic ethanol exposed mouse. Brain Res 815: 89-97. (Pubitemid 29225228)
250. Ortiz S, Oliva JM, Perez-Rial S, Palomo T, Manzanares J (2004) Chronic ethanol consumption regulates cannabinoid CB1 receptor gene expression in selected regions of rat brain. Alcohol Alcohol 39: 88-92. (Pubitemid 38386881)
251. Vinod KY, Maccioni P, Garcia-Gutierrez MS, Femenia T, Xie S, et al. (2012) Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats. Addiction Biology 17: 62-75.
252. Vinod KY, Yalamanchili R, Xie S, Cooper TB, Hungund BL (2006) Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. Neurochemistry International 49: 619-625. (Pubitemid 44528092)
253. Rimondini R, Arlinde C, Sommer W, Heilig M (2002) Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. Faseb Journal 16: 27-35. (Pubitemid 34027947)
254. Mitrirattanakul S, Lopez-Valdes HE, Liang J, Matsuka Y, Mackie K, et al. (2007) Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alcohol withdrawal and dependence. Alcohol Clin Exp Res 31: 855-867. (Pubitemid 46587662)
255. Adermark L, Jonsson S, Ericson M, Soderpalm B (2011) Intermittent ethanol consumption depresses endocannabinoid-signaling in the dorsolateral striatum of rat. Neuropharmacology 61: 1160-1165.
256. Feuerecker M, Hauer D, Gresset T, Lassas S, Kaufmann I, et al. (2012) Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans. Alcohol and Alcoholism 47: 226-232.
257. Vinod KY, Kassir SA, Hungund BL, Cooper TB, Mann JJ, et al. (2010) Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. Journal of Psychiatric Research 44: 591-597.
258. Gonzalez S, Cascio MG, Fernández-Ruiz J, Fezza F, Di Marzo V, et al. (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research 954: 73-81. (Pubitemid 35223443)
259. Penetar DM, Kouri EM, Gross MM, McCarthy EM, Rhee CK, et al. (2005) Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug Alcohol Depend 79: 211-223. (Pubitemid 40942111)
260. Balerio GN, Aso E, Maldonado R (2006) Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl) 184: 504-513. (Pubitemid 43255867)
261. Le Foll B, Wiggins M, Goldberg SR (2006) Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of Delta-9-tetrahydrocannabinol in rats. Behav Pharmacol 17: 195-199.
262. Pryor GT, Larsen FF, Husain S, Braude MC (1978) Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacol Biochem Behav 8: 295-318. (Pubitemid 8313406)
263. Solinas M, Scherma M, Tanda G, Wertheim CE, Fratta W, et al. (2007) Nicotinic facilitation of delta-9-tetrahydrocannabinol discrimination involves endogenous anandamide. Journal of Pharmacology and Experimental Therapeutics 321: 1127-1134. (Pubitemid 46762677)
264. 9-tetrahydrocannabinol and nicotine. British Journal of Pharmacology 135: 564-578.
265. Jafari MR, Golmohammadi S, Ghiasvand F, Zarrindast MR, Djahanguiri B (2007) Influence of nicotinic receptor modulators on CB2 cannabinoid receptor agonist (JWH133)-induced antinociception in mice. Behav Pharmacol 18: 691-697. (Pubitemid 47524896)
266. Cippitelli A, Astarita G, Duranti A, Caprioli G, Ubaldi M, et al. (2011) Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect ofFAAH inhibition. PLoS ONE 6.
267. 2 subtype. Brain Research 1115: 16-25.
268. Buczynski MW, Polis IY, Parsons LH (2013) The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area. Neuropsychopharmacology 38: 574-584.
269. Marco EM, Llorente R, Moreno E, Biscaia JM, Guaza C, et al. (2006) Adolescent exposure to nicotine modifies acute functional responses to cannabinoid agonists in rats. Behav Brain Res 172: 46-53. (Pubitemid 44063551)
270. Werling LL, Reed SC, Wade D, Izenwasser S (2009) Chronic nicotine alters cannabinoid-mediated locomotor activity and receptor density in periadolescent but not adult male rats. International Journal of Developmental Neuroscience 27: 263-269.
271. Robinson L, Goonawardena AV, Pertwee R, Hampson RE, Platt B, et al. (2010) WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. Behavioural Brain Research 208: 584-592.
272. Bell J (1857) On the haschisch or Cannabis indica. Boston Medical and Surgical Journal 56: 209-216.
273. Hoffman AF, Laaris N, Kawamura M, Masino SA, Lupica CR (2010) Control of cannabinoid CB1 receptor function on glutamate axon terminals by endogenous adenosine acting at A1 receptors. Journal of Neuroscience 30: 545-555.
274. Selley DE, Cassidy MP, Martin BR, Sim-Selley LJ (2004) Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum. Mol Pharmacol 66: 1275-1284. (Pubitemid 39411067)
275. McPartland JM, Mitchell JA (1997) Caffeine and chronic back pain. Archives of Physical Medicine and Rehabilitation 78: 61-63. (Pubitemid 27034246)
276. Consroe P, Jones B, Laird H, 2nd (1976) EEG and behavioral effects of delta9-tetrahydrocannabinol in combination with stimulant drugs in rabbits. Psychopharmacology (Berl) 50: 47-52.
277. Rossi S, De Chiara V, Musella A, Mataluni G, Sacchetti L, et al. (2009) Caffeine drinking potentiates cannabinoid transmission in the striatum: Interaction with stress effects. Neuropharmacology 56: 590-597.
278. 9-tetrahydrocannabinol on spatial memory. Neuropsychopharmacology 36: 472-487.
279. Mechoulam R, Fride E, Di Marzo V (1998) Endocannabinoids. Eur J Pharmacol 359: 1-18. (Pubitemid 28515716)
280. McPartland JM, Guy GW (2004) The evolution of Cannabis and coevolution with the cannabinoid receptor - a hypothesis. In: Guy GW, Robson R, Strong K, Whittle B, editors. The Medicinal Use of Cannabis. London: Royal Society of Pharmacists. pp. 71-102.
281. Cichewicz DL, Welch SP (2001) Opioid and cannabinoid receptor protein levels following chronic treatment. FASEB Journal 15: A228-A228.
282. Romero J, Garcia L, Fernandez-Ruiz JJ, Cebeira M, Ramos JA (1995) Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta-9-tetrahydrocannabinol. Pharmacology Biochemistry and Behavior 51: 731-737.
283. Zhuang S, Kittler J, Grigorenko EV, Kirby MT, Sim LJ, et al. (1998) Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res Mol Brain Res 62: 141-149. (Pubitemid 29010381)
284. 35S]GTPγS autoradiography in rat brain. Journal of Neuroscience 16: 8057-8066.
285. Burstein SH, Hunter SA (1995) Stimulation of anandamide biosynthesis in N-18TG2 neuroblastoma cells by delta-9-tetrahydrocannabinol (THC). Biochemical Pharmacology 49: p855-858.
286. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. Journal of Neurochemistry 73: 2447-2459.
287. 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology 35: 1775-1787.
288. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, et al. (2000) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of D9-tetrahydrocannabinol-tolerant rats. Journal of Neurochemistry 74: 1627-1635. (Pubitemid 30163985)
289. Villares J (2007) Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 145: 323-334.
290. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, et al. (2012) Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry 17: 642-649.
291. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, et al. (2008) Blunted Psychotomimetic and Amnestic Effects of Delta-9- Tetrahydrocannabinol in Frequent Users of Cannabis. Neuropsychopharmacology.
292. Rotter A, Bayerlein K, Hansbauer M, Weiland J, Sperling W, et al. (2013) CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence. European Addiction Research 19: 13-20.
293. 9- Tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 49: 1170-1177.
294. Hsieh C, Brown S, Derleth C, Mackie K (1999) Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73: 493-501. (Pubitemid 29339821)
295. Fan F, Compton DR, Ward S, Melvin L, Martin BR (1994) Development of cross-tolerance between delta-9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. Journal of Pharmacology and Experimental Therapeutics 271: 1383-1390. (Pubitemid 24382649)
296. Luk T, Jin WZ, Zvonok A, Lu D, Lin XZ, et al. (2004) Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. British Journal of Pharmacology 142: 495-500. (Pubitemid 38869863)
297. 9-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. Journal of Pharmacology and Experimental Therapeutics 303: 36-44.
298. 9- tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Neuropharmacology 59: 121-127.
299. 9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Molecular Pharmacology 55: 8-13.
300. Straiker A, Mackie K (2005) Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. Journal of Physiology-London 569: 501-517. (Pubitemid 41830118)
301. Gonsiorek W, Lunn C, Fan XD, Narula S, Lundell D, et al. (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Molecular Pharmacology 57: 1045-1050. (Pubitemid 30253390)
302. 1 receptor-dependent G-protein activation in rat cerebellar membranes. British Journal of Pharmacology 134: 664-672.
303. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773-778. (Pubitemid 27375156)
304. 9- tetrahydrocannabinol and other cannnabinoids. Journal of Pharmacology and Experimental Therapeutics 300: 34-42.
305. Mato S, Chevaleyre V, Robbe D, Pazos A, Castillo PE, et al. (2004) A single invivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. Nat Neurosci 7: 585-586. (Pubitemid 38691895)
306. 9-Tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 46: 709-715.
307. 9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate. Molecular Pharmacology 75: 892-900.
308. Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, et al. (1997) Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur J Pharmacol 336: 295-298. (Pubitemid 27464878)
309. Aceto MD, Scates SM, Razdan RK, Martin BR (1998) Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. Journal of Pharmacology and Experimental Therapeutics 287: 598-605. (Pubitemid 29133659)
310. Fride E (1995) Anandamides: tolerance and cross-tolerance to delta-9-tetrahydrocannabinol. Brain Research 697: 83-90.
311. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287: 884-888. (Pubitemid 29131596)
312. Glass M, Northup JK (1999) Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 56: 1362-1369.
313. Fride E, Barg J, Levy R, Saya D, Heldman E, et al. (1995) Low doses of anandamides inhibit pharmacological effects of delta-9-tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics 272: 699-707.
314. Pertwee RG, Stevenson LA, Griffin G (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. British Journal of Pharmacology 110: 1483-1490. (Pubitemid 23360982)
315. Vann RE, Walentiny DM, Burston JJ, Tobey KM, Gamage TF, et al. (2012) Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride. Neuropharmacology 62: 1019-1027.
316. Suplita RL, Eisenstein SA, Neely MH, Moise AM, Hohmann AG (2008) Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. Neuropharmacology 54: 161-171. (Pubitemid 350299417)
317. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, et al. (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proceedings of the National Academy of Sciences of the United States of America 106: 20270-20275.
318. McPartland JM, Pruitt PL (1999) Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana. Alternative Therapies in Health and Medicine 5: 57-62.
319. McPartland JM, Russo EB (2001) Cannabis and cannabis extracts: Greater than the sum of their parts? Journal of Cannabis Therapeutics 1: 103-132.
320. 9- tetrahydrocannabinol via CB1 receptor-dependent mechanism. Brain Research 1188: 157-164.
321. Wolf SA, Bick-Sander A, Fabel K, Leal-Galicia P, Tauber S, et al. (2010) Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Communication and Signaling 8.
322. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology 134: 845-852. (Pubitemid 33016156)
323. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, et al. (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology 163: 1479-1494.
324. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, et al. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nature Neuroscience 13: 1113-1121.
325. Watanabe S, Doshi M, Hamazaki T (2003) n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69: 51-59. (Pubitemid 37421501)
326. Matias I, Carta G, Murru E, Petrosino S, Banni S, et al. (2008) Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 1781: 52-60.
327. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, et al. (2008) Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 1781: 200-212.
328. Kirkham TC, Williams CM, Fezza F, Di Marzo V (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology 136: 550-557. (Pubitemid 34717699)
329. Hanus L, Avraham Y, Ben-Shushan D, Zolotarev O, Berry EM, et al. (2003) Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Research 983: 144-151. (Pubitemid 36952575)
330. Cottone E, Guastalla A, Pomatto V, Campantico E, Di Marzo V, et al. (2009) Goldfish CB1 mRNA expression is affected by fasting and anandamide administration. Neuroreport 20: 595-599.
331. Valenti M, Cottone E, Martinez R, De Pedro N, Rubio M, et al. (2005) The endocannabinoid system in the brain of Carassius auratus and its possible role in the control of food intake. Journal of Neurochemistry 95: 662-672. (Pubitemid 41567159)
332. Guijarro A, Osei-Hyiaman D, Harvey-White J, Kunos G, Suzuki S, et al. (2008) Sustained weight loss after roux-en-y gastric bypass is characterized by down regulation of endocannabinoids and mitochondrial function. Annals of Surgery 247: 779-790. (Pubitemid 351591513)
333. Jelsing J, Larsen PJ, Vrang N (2009) The effect of leptin receptor deficiency and fasting on cannabinoid receptor 1 mRNA expression in the rat hypothalamus, brainstem and nodose ganglion. Neuroscience Letters 463: 125-129.
334. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, et al. (2007) Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochemical and Biophysical Research Communications 354: 427-433. (Pubitemid 46172454)
335. Rossi S, Furlan R, De Chiara V, Musella A, Lo Giudice T, et al. (2009) Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. Neurobiology of Disease 36: 51-59.
336. De Chiara V, Errico F, Musella A, Rossi S, Mataluni G, et al. (2010) Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum. Neuropsychopharmacology 35: 374-387.
337. da Silva SG, Araujo BHS, Cossa AC, Scorza FA, Cavalheiro EA, et al. (2010) Physical exercise in adolescence changes CB1 cannabinoid receptor expression in the rat brain. Neurochemistry International 57: 492-496.
338. Hill MN, Titterness AK, Morrish AC, Carrier EJ, Lee TTY, et al. (2010) Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. Hippocampus 20: 513-523.
339. Yasari S, Prud'homme D, Tesson F, Jankowski M, Gutkowska J, et al. (2012) Effects of exercise training on molecular markers of lipogenesis and lipid partitioning in fructose-induced liver fat accumulation. J Nutr Metab 2012: 181687.
340. Basavarajappa BS, Hungund BL (1999) Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N- arachidonoylphosphatidylethanolamine in SK-N-SH cells. Journal of Neurochemistry 72: 522-528. (Pubitemid 29055213)
341. Basavarajappa BS, Saito M, Cooper TB, Hungund BL (2000) Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons. Biochimica Et Biophysica Acta-Molecular Basis of Disease 1535: 78-86.
342. Basavarajappa BS, Saito M, Cooper TB, Hungund BL (2003) Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. European Journal of Pharmacology 466: 73-83. (Pubitemid 36385092)
343. Burkey TH, Quock RM, Consroe P, Roeske WR, Yamamura HI (1997) delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. Eur J Pharmacol 323: R3-4. (Pubitemid 27152285)
344. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sciences 63: PL1-6.